Comparison · NCT02913612-b1fc15ff
0.25% Timolol Treatment vs 0.5% Timolol Treatment: Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 0.25% Timolol Treatment vs 0.5% Timolol Treatment: Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm. Trial comparisons, record NCT02913612-b1fc15ff. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02913612-b1fc15ff
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.727 | 0.582 | 0.837 | wilson | |
| Risk in group 2 | 0.694 | 0.555 | 0.805 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0334 | -0.15 | 0.21 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.809 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.479 | 2.89 | log | |
| Number needed to treat, for one more participant with the outcome on 0.25% Timolol Treatment than on 0.5% Timolol Treatment | 29.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 0.25% Timolol Treatment | Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.~0.25% Timolol Maleate Gel Forming Solution: 50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution | 32 | 44 | OG000 |
| Group 2 | 0.5% Timolol Treatment | Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.~0.5% Timolol Maleate Gel Forming Solution: 50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution | 34 | 49 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm
- Description
Comparison of partial response of hemangioma color (partial response or greater as assessed by VAS-color) between the two treatment arms. Partial response: \>30% and up to 80% reduction in color of hemangioma.
- Time frame
- 180 days
- Population
- Only participants with evaluable data were included in the analysis.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
- NCT number
- NCT02913612
- Phases
- PHASE2
- Conditions
- Infantile Hemangioma
- Interventions
- 0.25% Timolol Maleate Gel Forming Solution, 0.5% Timolol Maleate Gel Forming Solution
- Lead sponsor
- Kanecia Obie Zimmerman
- Results first posted
- 2022-11-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02913612?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02913612-b1fc15ff